Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.
Sarah Crafton, MD
Advertisement
Articles by Sarah Crafton, MD
Sarah Crafton, MD, discusses the integration of mirvetuximab soravtansine-gynx into clinical practice in the treatment of ovarian cancer.
Sarah Crafton, MD, discusses novel therapeutic targets under investigation in patients with ovarian cancer.
Sarah Crafton, MD, discusses the personalized choice of undergoing secondary cytoreduction for patients with ovarian cancer.
Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.
Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses secondary surgical cytoreduction in recurrent ovarian cancer.
Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Crafton on Optimizing Treatment Selection in Recurrent Ovarian CancerPublished: November 28th 2019 | Updated:
Dr. Crafton on Secondary Surgical Cytoreduction in Ovarian CancerPublished: December 4th 2019 | Updated:
Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian CancerPublished: December 21st 2019 | Updated:
Dr. Crafton on Considerations for Secondary Cytoreduction in Ovarian CancerPublished: February 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5